{"id":5544,"date":"2023-11-30T08:10:04","date_gmt":"2023-11-30T14:10:04","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5544"},"modified":"2025-06-27T11:27:51","modified_gmt":"2025-06-27T16:27:51","slug":"nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/","title":{"rendered":"Terap\u00e9utica con nanoscopios se presentar\u00e1 en la XIII Cumbre de Innovaci\u00f3n en Oftalmolog\u00eda (OIS)"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">30 de noviembre de 2023<\/span><\/span> \u2014\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4038340-1&h=2546362476&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que\u00a0<span class=\"xn-person\">Jared Esteban<\/span>, PhD, Vicepresidente de Estrategia y Desarrollo de Negocio, presentar\u00e1 en el 13<sup>th<\/sup>\u00a0Anual\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4038340-1&h=4187981707&u=https%3A%2F%2Fois.net%2F&a=Ophthalmology+Innovation+Summit\" target=\"_blank\" rel=\"nofollow noopener\">Cumbre de Innovaci\u00f3n en Oftalmolog\u00eda<\/a>\u00a0(OIS) que se lleva a cabo desde\u00a0<span class=\"xn-chron\">1-2 de diciembre<\/span>\u00a0en\u00a0<span class=\"xn-location\">San Diego, California<\/span>. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n<p><b>T\u00edtulo:<\/b>\u00a0Pioneros en una nueva ola de terapias optogen\u00e9ticas para la restauraci\u00f3n de la visi\u00f3n<\/p>\n<p><b>T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Escaparate de innovaci\u00f3n Retina<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:<\/b>\u00a0<span class=\"xn-chron\">2 de diciembre de 2023<\/span><br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:<\/b>\u00a011:<span class=\"xn-chron\">05 a.m. hora del este<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:<\/b>\u00a0Hotel Omni San Diego<br class=\"dnr\" \/><b>Presentador:<\/b>\u00a0Jared Stephens, PhD, vicepresidente de estrategia y desarrollo empresarial<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Stephens ofrecer\u00e1 una actualizaci\u00f3n corporativa sobre las actividades recientes y futuras de Nanoscope.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares de la fase RESTORE.\u00a0<span class=\"xn-money\">2b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Nov. 30, 2023 \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Jared Stephens, PhD, Vice President of Strategy and Business Development, will present at the 13th\u00a0Annual\u00a0Ophthalmology Innovation Summit\u00a0(OIS) taking place from\u00a0December 1-2\u00a0in\u00a0San Diego, California. Details for the presentation are as follows: [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5545,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-30T14:10:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:27:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII\",\"datePublished\":\"2023-11-30T14:10:04+00:00\",\"dateModified\":\"2025-06-27T16:27:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/\"},\"wordCount\":244,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_OIS_2023_2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/\",\"name\":\"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_OIS_2023_2.jpg\",\"datePublished\":\"2023-11-30T14:10:04+00:00\",\"dateModified\":\"2025-06-27T16:27:51+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_OIS_2023_2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/NSCOPE_LI_OIS_2023_2.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/11\\\/30\\\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus productos en la XIII Cumbre de Innovaci\u00f3n en Oftalmolog\u00eda (OIS) - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2023-11-30T14:10:04+00:00","article_modified_time":"2025-06-27T16:27:51+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII","datePublished":"2023-11-30T14:10:04+00:00","dateModified":"2025-06-27T16:27:51+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/"},"wordCount":244,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/","url":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/","name":"Nanoscope Therapeutics presentar\u00e1 sus productos en la XIII Cumbre de Innovaci\u00f3n en Oftalmolog\u00eda (OIS) - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","datePublished":"2023-11-30T14:10:04+00:00","dateModified":"2025-06-27T16:27:51+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/11\/NSCOPE_LI_OIS_2023_2.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2023\/11\/30\/nanoscope-therapeutics-to-present-at-ophthalmology-innovation-summit-ois-xiii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5544"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5544\/revisions"}],"predecessor-version":[{"id":9062,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5544\/revisions\/9062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5545"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}